Industry Research Reports

Home > Reports > Service & Software > Global Molecular Affinity Detection Service Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Global Molecular Affinity Detection Service Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Industry: Service & Software

Published Date: 2026-08-06

Pages: 136 Pages

Report ld: 6986053

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

biaoTi KEY FINDINGS

Biopharmaceutical research remains the primary commercial demand source

Kinetic characterization generates higher value than basic affinity measurement

SPR and BLI dominate real-time binding analysis workflows

High-throughput antibody screening supports substantial project demand

Orthogonal validation improves confidence in complex interaction results

Scientific interpretation determines premium service differentiation

Molecular Affinity Detection Service Market Size(US$)

CAGR 2026-2032

11.5%

Market Size,2032

USD 1,330

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 692 million

Market Forecast in 2032(Value)

US$ 1,330 million

CAGR

11.5%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Molecular Affinity Detection Service market size was US$ 621 million in 2025 and is forecast to reach a readjusted size of US$ 1330 million by 2032 with a CAGR of 11.5% during the forecast period 2026-2032.

Molecular Affinity Detection Service refers to commissioned analytical services that determine whether two molecules interact and quantitatively characterize their binding strength, association and dissociation kinetics, thermodynamic properties, specificity, competition behavior, and interaction mechanisms. The research scope covers qualitative binding screening, quantitative affinity measurement, kinetic characterization, thermodynamic analysis, competition assays, epitope binning, cross-reactivity evaluation, and high-content mechanism studies. Core technologies include surface plasmon resonance, bio-layer interferometry, microscale thermophoresis, isothermal titration calorimetry, grating-coupled interferometry, and complementary biophysical methods. Typical analytes include antibodies, antigens, recombinant proteins, peptides, nucleic acids, receptors, small molecules, targeted protein degraders, viral particles, and biomolecular complexes. Key output parameters include KD, KA, ka, kd, EC50, IC50, binding stoichiometry, ΔH, ΔS, ΔG, and relative binding response. Service performance is evaluated through measurable affinity range, kinetic range, throughput, sample consumption, molecular-weight compatibility, method-development difficulty, reproducibility, turnaround time, and interpretation depth. The market mainly serves pharmaceutical and biotechnology development, diagnostics, biopharmaceutical manufacturing and quality control, academic research, vaccines, and emerging therapeutic modalities.

biaoTi MARKET TRENDS

Molecular Affinity Detection Service is shifting from isolated equilibrium-affinity measurement toward integrated workflows combining binding confirmation, kinetics, thermodynamics, competition, epitope relationships, cross-reactivity, and mechanism assessment. Customers increasingly require services to answer not only whether two molecules bind, but also how rapidly binding occurs, how long the complex remains stable, whether multiple molecules compete for the same binding region, and whether the observed interaction is relevant to biological function. SPR and BLI remain central to real-time label-free analysis, while MST, ITC, and other orthogonal techniques are increasingly used to reduce platform-specific bias and improve confidence in candidate selection. Automation, parallel detection channels, multiwell formats, lower sample consumption, and improved fitting software are increasing throughput and shortening project cycles. Demand is also extending from conventional antibody–antigen and protein–small-molecule systems toward bispecific antibodies, ADCs, nanobodies, nucleic-acid therapeutics, PROTACs, molecular glues, membrane proteins, viral particles, and multicomponent complexes. The long-term direction is a decision-oriented service model that combines affinity data with structural information, biological activity, candidate quality, and developability rather than delivering isolated KD values.

MARKET SEGMENTATION

By Company

Charles River Laboratories
WuXi Biologics
Pharmaron
Evotec
Sygnature Discovery
Reaction Biology
Domainex
Selvita
NovAliX
2bind
RoukenBio
ProteoGenix
Creative Biolabs
Ichor Life Sciences
GenScript Biotech
Sino Biological
Viva Biotech
KMD Bioscience
Toray Research Center
Fukushima Cell Factory

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Binary Interaction Service (2 Molecular Components)
Ternary Interaction Service (3 Molecular Components)
Multi-Component Interaction Service (≥4 Molecular Components)

Segment by Application

Biopharmaceutical Industry
Research Institutes and Universities
Food Industry
Others

Segment by Category

Low-Throughput Service
Medium-Throughput Service
High-Throughput Service

Segment by Division

Qualitative Affinity Screening
Quantitative Affinity Determination

biaoTi MARKET DYNAMICS

Drivers

Market demand is driven by continued investment in innovative drug discovery, antibody engineering, biologics development, biosimilar characterization, diagnostic reagent development, vaccine research, and advanced therapeutic modalities. Molecular binding is fundamental to target engagement, receptor activation, antibody recognition, enzyme inhibition, targeted delivery, and diagnostic detection, making affinity and kinetic characterization an important part of candidate screening and optimization. Pharmaceutical and biotechnology companies increasingly outsource these studies because SPR, BLI, MST, ITC, and related platforms require substantial equipment investment, specialized assay-development expertise, and experienced data interpretation. Outsourcing also enables customers to access multiple technologies without maintaining separate internal laboratories. The expansion of high-throughput antibody discovery, AI-designed proteins, fragment screening, bispecific antibodies, ADCs, targeted protein degradation, and nucleic-acid therapeutics is increasing both the number and complexity of interactions requiring analysis. Biopharmaceutical process development and quality control further support demand for binding-activity comparison, Fc receptor analysis, residual impurity testing, batch consistency evaluation, and biosimilar comparability studies.

Restraints

Market expansion is restrained by assay complexity, sample-quality dependence, technology-specific bias, and limited comparability across different experimental conditions. Surface-based methods can be influenced by immobilization direction, surface density, mass-transfer limitation, rebinding, nonspecific adsorption, and regeneration conditions. Solution-based methods may require fluorescence labeling, higher sample concentrations, or sufficient reaction heat. Proteins that aggregate, degrade, bind nonspecifically, or remain unstable in the selected buffer can produce unreliable data and require repeated method optimization. Weak binding, extremely slow dissociation, multivalent interactions, heterogeneous samples, membrane proteins, and ternary complexes are difficult to fit using simple binding models. Sample preparation and high-quality purified protein supply may become larger project bottlenecks than instrument capacity. Customers may also hesitate to outsource confidential targets or valuable compounds, while smaller research programs can be sensitive to method-development fees, consumable costs, and repeat-testing expenses. These factors create substantial differences in data quality and scientific value among services that appear similar at the quotation stage.

Opportunities

The strongest opportunities lie in high-throughput biologics screening, complex-modality characterization, orthogonal verification, integrated protein-to-data workflows, and application-specific assay packages. Large antibody libraries require rapid affinity ranking, koff screening, epitope binning, cross-reactivity analysis, dual-target binding assessment, and Fc receptor characterization. PROTACs and molecular glues generate demand for binary and ternary complex measurement, cooperativity analysis, residence-time evaluation, and specialized kinetic models. AI-generated antibodies, peptides, proteins, and enzymes create additional experimental-validation requirements. Service providers can increase project value by combining recombinant protein production, assay development, SPR or BLI screening, MST or ITC confirmation, structural analysis, functional testing, and developability evaluation. Additional opportunities are emerging in diagnostic reagent development, vaccines, cell and gene therapy, nucleic-acid medicines, food-allergen research, animal health, agricultural biotechnology, biosensors, and biomaterials. Providers with automated instruments, multiple sensor chemistries, broad molecular compatibility, and strong scientific consulting capabilities are positioned to move from test execution toward integrated discovery and development decision support.

Challenges

The industry faces long-term challenges in method standardization, cross-platform comparability, complex-data interpretation, scientific-talent availability, and quality management. KD, ka, and kd values can change when temperature, buffer composition, immobilization strategy, analyte concentration, valency, fitting model, and instrument technology vary. Transparent experimental documentation, appropriate controls, and technically justified models are therefore essential. High-throughput capacity must be balanced with rigorous assay design because rapid measurement cannot compensate for poor protein quality, unsuitable controls, or incorrect data fitting. Multi-site pharmaceutical projects may also require methods to be transferred among CROs, internal laboratories, and quality-control environments, increasing the importance of reproducibility, traceability, and standard operating procedures. Service providers must protect customer intellectual property, maintain instrument uptime, secure critical consumables, and prevent delays caused by unstable samples or repeated optimization. As more laboratories acquire similar equipment, sustainable differentiation increasingly depends on scientific judgment, method-development capability, problem-solving experience, and integration with broader research workflows.

biaoTi VALUE CHAIN ANALYSIS

The upstream value chain includes SPR, BLI, MST, ITC, GCI, microfluidic, and complementary biophysical instruments, as well as sensor chips, biosensors, capillaries, microplates, coupling reagents, buffers, fluorescent labels, reference compounds, recombinant proteins, antibodies, and analysis software. Instrument suppliers determine the sensitivity, throughput, kinetic range, automation level, and fitting capabilities available to service laboratories. Protein-expression companies, reagent suppliers, sample-preparation specialists, and laboratory-automation providers also influence project success because analyte purity, biological activity, homogeneity, concentration accuracy, and storage stability are critical input conditions. High-value equipment, recurring consumables, maintenance contracts, software licenses, laboratory facilities, and experienced scientific personnel form the principal cost base.

Midstream service providers create value through project consultation, technology selection, sample-quality assessment, immobilization or labeling design, assay development, concentration-series planning, control selection, instrument execution, curve fitting, model evaluation, repeat verification, scientific interpretation, and report delivery. Basic binding confirmation and single-parameter affinity measurement are relatively standardized, whereas membrane proteins, weak interactions, multivalent systems, epitope binning, high-throughput campaigns, and ternary complexes require more specialist labor and support higher service prices. Downstream customers include pharmaceutical and biotechnology companies, diagnostic developers, vaccine manufacturers, academic institutions, research organizations, food and agricultural biotechnology companies, and biosensor developers. Profitability depends on instrument utilization, assay success rate, consumable efficiency, scientific-labor productivity, customer retention, repeat projects, and the proportion of customized high-value services.

biaoTi SEGMENT INSIGHTS

By analytical depth, Molecular Affinity Detection Service can be divided into qualitative affinity screening, quantitative affinity measurement, kinetic affinity characterization, thermodynamic characterization, and high-content mechanism analysis. Qualitative screening confirms whether binding occurs and supports early candidate elimination. Quantitative measurement provides KD, EC50, IC50, or relative affinity rankings and represents a common entry-level service. Kinetic characterization generates ka, kd, and KD and is commercially important in antibody discovery, lead optimization, receptor-binding studies, and biosimilar comparison because molecules with similar equilibrium affinity may have substantially different association and dissociation behavior. Thermodynamic characterization provides binding stoichiometry, enthalpy, entropy, and free-energy information, supporting deeper interpretation of molecular recognition.

High-content mechanism services combine kinetics, thermodynamics, competition, epitope binning, cross-reactivity, multivalent binding, or structural and functional validation. These services are less standardized but generally carry higher scientific and commercial value. By throughput, the market ranges from customized low-throughput analysis to automated ultra-high-throughput screening. SPR is widely used for sensitive kinetic analysis and small-molecule studies, BLI supports flexible parallel screening, MST enables low-sample solution-phase measurement, and ITC provides direct thermodynamic characterization. By interaction complexity, services can be divided into binary, ternary, multicomponent, and heterogeneous-system analysis. The fastest-developing opportunities are concentrated in high-throughput biologics screening, ternary-complex characterization, orthogonal validation, and integrated high-content mechanism analysis.

biaoTi DOWNSTREAM MARKET OPPORTUNITIES

Pharmaceutical and biotechnology companies constitute the principal downstream market, covering small-molecule drugs, therapeutic antibodies, recombinant proteins, vaccines, biosimilars, ADCs, bispecific antibodies, nanobodies, protein degraders, and nucleic-acid therapeutics. Diagnostic companies require antigen–antibody pairing, biomarker-binding evaluation, cross-reactivity analysis, and reagent optimization. Biopharmaceutical manufacturers use affinity services for cell-line screening, product quantification, binding-activity assessment, residual impurity testing, batch consistency, and comparability analysis. Academic and life-science institutions generate demand for protein–protein, protein–nucleic-acid, receptor–ligand, enzyme–inhibitor, lipid, and carbohydrate interaction studies. Additional opportunities exist in food allergens, functional ingredients, veterinary diagnostics, agricultural biotechnology, biomaterials, cosmetics, and biosensors. Higher-value projects generally involve scarce samples, complex assay development, multiple detection technologies, mechanism interpretation, or integration with upstream protein production and downstream structural or functional validation.

biaoTi REPORT SCOPE

The global Molecular Affinity Detection Service market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.

biaoTi CHAPTER OUTLINE

Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)

Chapter 2: Quantitative analysis of Molecular Affinity Detection Service market size and growth potential at global, regional, and country levels

Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)

Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets

Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities

Chapter 6: Regional revenue breakdown by company, type, application and customer

Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments

Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies

Chapter 9: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Molecular Affinity Detection Service value chain, addressing:

- Market entry risks/opportunities by region

- Product mix optimization based on local practices

- Competitor tactics in fragmented vs. consolidated markets

biaoTi QYRESEARCH'S STRENGTHS

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market by Type

1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032

1.2.2 Binary Interaction Service (2 Molecular Components)

1.2.3 Ternary Interaction Service (3 Molecular Components)

1.2.4 Multi-Component Interaction Service (≥4 Molecular Components)

1.3 Market by Application

1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032

1.3.2 Biopharmaceutical Industry

1.3.3 Research Institutes and Universities

1.3.4 Food Industry

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Molecular Affinity Detection Service Market Perspective (2021-2032)

2.2 Global Market Size by Region: 2021 vs 2025 vs 2032

2.3 Global Molecular Affinity Detection Service Market Share by Revenue, by Region (2021-2026)

2.4 Global Molecular Affinity Detection Service Revenue Forecast by Region (2027-2032)

2.5 Major Regions and Emerging Markets Analysis

2.5.1 North America Molecular Affinity Detection Service Market Size and Prospective (2021-2032)

2.5.2 Europe Molecular Affinity Detection Service Market Size and Prospective (2021-2032)

2.5.3 China Molecular Affinity Detection Service Market Size and Prospective (2021-2032)

2.5.4 Japan Molecular Affinity Detection Service Market Size and Prospective (2021-2032)

3 Breakdown Data by Type

3.1 Global Molecular Affinity Detection Service Historical Market Size by Type (2021-2026)

3.2 Global Molecular Affinity Detection Service Forecasted Market Size by Type (2027-2032)

3.3 Representative Players for Different Types of Molecular Affinity Detection Service

4 Breakdown Data by Application

4.1 Global Molecular Affinity Detection Service Historical Market Size by Application (2021-2026)

4.2 Global Molecular Affinity Detection Service Forecasted Market Size by Application (2027-2032)

4.3 New Sources of Growth in Molecular Affinity Detection Service Applications

5 Competitive Landscape by Players

5.1 Global Top Players by Revenue

5.1.1 Global Top Molecular Affinity Detection Service Players by Revenue (2021-2026)

5.1.2 Global Molecular Affinity Detection Service Market Share by Revenue, by Players (2021-2026)

5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

5.3 Players Covered: Ranking by Molecular Affinity Detection Service Revenue

5.4 Global Molecular Affinity Detection Service Market Concentration Analysis

5.4.1 Global Molecular Affinity Detection Service Market Concentration Ratio (CR5 and HHI)

5.4.2 Global Top 10 and Top 5 Companies by Molecular Affinity Detection Service Revenue in 2025

5.5 Global Key Players of Molecular Affinity Detection Service Head Offices and Areas Served

5.6 Global Key Players of Molecular Affinity Detection Service, Product and Application

5.7 Global Key Players of Molecular Affinity Detection Service, Date of Entry into This Industry

5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America Molecular Affinity Detection Service Revenue by Company (2021-2026)

6.1.2 North America Market Size by Type

6.1.2.1 North America Molecular Affinity Detection Service Market Size by Type (2021-2026)

6.1.2.2 North America Molecular Affinity Detection Service Market Share by Type (2021-2026)

6.1.3 North America Market Size by Application

6.1.3.1 North America Molecular Affinity Detection Service Market Size by Application (2021-2026)

6.1.3.2 North America Molecular Affinity Detection Service Market Share by Application (2021-2026)

6.1.4 North America Molecular Affinity Detection Service Major Customers

6.1.5 North America Market Trends and Opportunities

6.2 Europe Market: Players, Segments, Downstream and Major Customers

6.2.1 Europe Molecular Affinity Detection Service Revenue by Company (2021-2026)

6.2.2 Europe Market Size by Type

6.2.2.1 Europe Molecular Affinity Detection Service Market Size by Type (2021-2026)

6.2.2.2 Europe Molecular Affinity Detection Service Market Share by Type (2021-2026)

6.2.3 Europe Market Size by Application

6.2.3.1 Europe Molecular Affinity Detection Service Market Size by Application (2021-2026)

6.2.3.2 Europe Molecular Affinity Detection Service Market Share by Application (2021-2026)

6.2.4 Europe Molecular Affinity Detection Service Major Customers

6.2.5 Europe Market Trends and Opportunities

6.3 China Market: Players, Segments, Downstream and Major Customers

6.3.1 China Molecular Affinity Detection Service Revenue by Company (2021-2026)

6.3.2 China Market Size by Type

6.3.2.1 China Molecular Affinity Detection Service Market Size by Type (2021-2026)

6.3.2.2 China Molecular Affinity Detection Service Market Share by Type (2021-2026)

6.3.3 China Market Size by Application

6.3.3.1 China Molecular Affinity Detection Service Market Size by Application (2021-2026)

6.3.3.2 China Molecular Affinity Detection Service Market Share by Application (2021-2026)

6.3.4 China Molecular Affinity Detection Service Major Customers

6.3.5 China Market Trends and Opportunities

6.4 Japan Market: Players, Segments, Downstream and Major Customers

6.4.1 Japan Molecular Affinity Detection Service Revenue by Company (2021-2026)

6.4.2 Japan Market Size by Type

6.4.2.1 Japan Molecular Affinity Detection Service Market Size by Type (2021-2026)

6.4.2.2 Japan Molecular Affinity Detection Service Market Share by Type (2021-2026)

6.4.3 Japan Market Size by Application

6.4.3.1 Japan Molecular Affinity Detection Service Market Size by Application (2021-2026)

6.4.3.2 Japan Molecular Affinity Detection Service Market Share by Application (2021-2026)

6.4.4 Japan Molecular Affinity Detection Service Major Customers

6.4.5 Japan Market Trends and Opportunities

7 Key Player Profiles

7.1 Charles River Laboratories

7.1.1 Charles River Laboratories Company Details

7.1.2 Charles River Laboratories Business Overview

7.1.3 Charles River Laboratories Molecular Affinity Detection Service Introduction

7.1.4 Charles River Laboratories Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.1.5 Charles River Laboratories Recent Development

7.2 WuXi Biologics

7.2.1 WuXi Biologics Company Details

7.2.2 WuXi Biologics Business Overview

7.2.3 WuXi Biologics Molecular Affinity Detection Service Introduction

7.2.4 WuXi Biologics Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.2.5 WuXi Biologics Recent Development

7.3 Pharmaron

7.3.1 Pharmaron Company Details

7.3.2 Pharmaron Business Overview

7.3.3 Pharmaron Molecular Affinity Detection Service Introduction

7.3.4 Pharmaron Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.3.5 Pharmaron Recent Development

7.4 Evotec

7.4.1 Evotec Company Details

7.4.2 Evotec Business Overview

7.4.3 Evotec Molecular Affinity Detection Service Introduction

7.4.4 Evotec Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.4.5 Evotec Recent Development

7.5 Sygnature Discovery

7.5.1 Sygnature Discovery Company Details

7.5.2 Sygnature Discovery Business Overview

7.5.3 Sygnature Discovery Molecular Affinity Detection Service Introduction

7.5.4 Sygnature Discovery Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.5.5 Sygnature Discovery Recent Development

7.6 Reaction Biology

7.6.1 Reaction Biology Company Details

7.6.2 Reaction Biology Business Overview

7.6.3 Reaction Biology Molecular Affinity Detection Service Introduction

7.6.4 Reaction Biology Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.6.5 Reaction Biology Recent Development

7.7 Domainex

7.7.1 Domainex Company Details

7.7.2 Domainex Business Overview

7.7.3 Domainex Molecular Affinity Detection Service Introduction

7.7.4 Domainex Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.7.5 Domainex Recent Development

7.8 Selvita

7.8.1 Selvita Company Details

7.8.2 Selvita Business Overview

7.8.3 Selvita Molecular Affinity Detection Service Introduction

7.8.4 Selvita Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.8.5 Selvita Recent Development

7.9 NovAliX

7.9.1 NovAliX Company Details

7.9.2 NovAliX Business Overview

7.9.3 NovAliX Molecular Affinity Detection Service Introduction

7.9.4 NovAliX Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.9.5 NovAliX Recent Development

7.10 2bind

7.10.1 2bind Company Details

7.10.2 2bind Business Overview

7.10.3 2bind Molecular Affinity Detection Service Introduction

7.10.4 2bind Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.10.5 2bind Recent Development

7.11 RoukenBio

7.11.1 RoukenBio Company Details

7.11.2 RoukenBio Business Overview

7.11.3 RoukenBio Molecular Affinity Detection Service Introduction

7.11.4 RoukenBio Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.11.5 RoukenBio Recent Development

7.12 ProteoGenix

7.12.1 ProteoGenix Company Details

7.12.2 ProteoGenix Business Overview

7.12.3 ProteoGenix Molecular Affinity Detection Service Introduction

7.12.4 ProteoGenix Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.12.5 ProteoGenix Recent Development

7.13 Creative Biolabs

7.13.1 Creative Biolabs Company Details

7.13.2 Creative Biolabs Business Overview

7.13.3 Creative Biolabs Molecular Affinity Detection Service Introduction

7.13.4 Creative Biolabs Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.13.5 Creative Biolabs Recent Development

7.14 Ichor Life Sciences

7.14.1 Ichor Life Sciences Company Details

7.14.2 Ichor Life Sciences Business Overview

7.14.3 Ichor Life Sciences Molecular Affinity Detection Service Introduction

7.14.4 Ichor Life Sciences Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.14.5 Ichor Life Sciences Recent Development

7.15 GenScript Biotech

7.15.1 GenScript Biotech Company Details

7.15.2 GenScript Biotech Business Overview

7.15.3 GenScript Biotech Molecular Affinity Detection Service Introduction

7.15.4 GenScript Biotech Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.15.5 GenScript Biotech Recent Development

7.16 Sino Biological

7.16.1 Sino Biological Company Details

7.16.2 Sino Biological Business Overview

7.16.3 Sino Biological Molecular Affinity Detection Service Introduction

7.16.4 Sino Biological Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.16.5 Sino Biological Recent Development

7.17 Viva Biotech

7.17.1 Viva Biotech Company Details

7.17.2 Viva Biotech Business Overview

7.17.3 Viva Biotech Molecular Affinity Detection Service Introduction

7.17.4 Viva Biotech Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.17.5 Viva Biotech Recent Development

7.18 KMD Bioscience

7.18.1 KMD Bioscience Company Details

7.18.2 KMD Bioscience Business Overview

7.18.3 KMD Bioscience Molecular Affinity Detection Service Introduction

7.18.4 KMD Bioscience Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.18.5 KMD Bioscience Recent Development

7.19 Toray Research Center

7.19.1 Toray Research Center Company Details

7.19.2 Toray Research Center Business Overview

7.19.3 Toray Research Center Molecular Affinity Detection Service Introduction

7.19.4 Toray Research Center Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.19.5 Toray Research Center Recent Development

7.20 Fukushima Cell Factory

7.20.1 Fukushima Cell Factory Company Details

7.20.2 Fukushima Cell Factory Business Overview

7.20.3 Fukushima Cell Factory Molecular Affinity Detection Service Introduction

7.20.4 Fukushima Cell Factory Revenue in Molecular Affinity Detection Service Business (2021-2026)

7.20.5 Fukushima Cell Factory Recent Development

8 Molecular Affinity Detection Service Market Dynamics

8.1 Molecular Affinity Detection Service Industry Trends

8.2 Molecular Affinity Detection Service Market Drivers

8.3 Molecular Affinity Detection Service Market Challenges

8.4 Molecular Affinity Detection Service Market Restraints

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Molecular Affinity Detection Service Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Global Molecular Affinity Detection Service Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 3. Global Market Molecular Affinity Detection Service Market Size (US$ Million) by Region:2021 vs 2025 vs 2032

Table 4. Global Molecular Affinity Detection Service Revenue (US$ Million) Market Share by Region (2021-2026)

Table 5. Global Molecular Affinity Detection Service Revenue Share by Region (2021-2026)

Table 6. Global Molecular Affinity Detection Service Revenue (US$ Million) Forecast by Region (2027-2032)

Table 7. Global Molecular Affinity Detection Service Revenue Share Forecast by Region (2027-2032)

Table 8. Global Molecular Affinity Detection Service Market Size by Type (2021-2026) & (US$ Million)

Table 9. Global Molecular Affinity Detection Service Market Share by Revenue, by Type (2021-2026)

Table 10. Global Molecular Affinity Detection Service Forecasted Market Size by Type (2027-2032) & (US$ Million)

Table 11. Global Molecular Affinity Detection Service Market Share by Revenue, by Type (2027-2032)

Table 12. Representative Players of Each Type

Table 13. Global Molecular Affinity Detection Service Market Size by Application (2021-2026) & (US$ Million)

Table 14. Global Molecular Affinity Detection Service Market Share by Revenue, by Application (2021-2026)

Table 15. Global Molecular Affinity Detection Service Forecasted Market Size by Application (2027-2032) & (US$ Million)

Table 16. Global Molecular Affinity Detection Service Market Share by Revenue, by Application (2027-2032)

Table 17. New Sources of Growth in Molecular Affinity Detection Service Applications

Table 18. Global Molecular Affinity Detection Service Revenue by Players (2021-2026) & (US$ Million)

Table 19. Global Molecular Affinity Detection Service Market Share by Players (2021-2026)

Table 20. Global Top Molecular Affinity Detection Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Molecular Affinity Detection Service as of 2025)

Table 21. Ranking of Global Top Molecular Affinity Detection Service Companies by Revenue (US$ Million) in 2025

Table 22. Global 5 Largest Players Market Share by Molecular Affinity Detection Service Revenue (CR5 and HHI) & (2021-2026)

Table 23. Global Key Players of Molecular Affinity Detection Service, Headquarters and Area Served

Table 24. Global Key Players of Molecular Affinity Detection Service, Product and Application

Table 25. Global Key Players of Molecular Affinity Detection Service, Date of Entry into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America Molecular Affinity Detection Service Revenue by Company (2021-2026) & (US$ Million)

Table 28. North America Molecular Affinity Detection Service Market Share by Revenue, by Company (2021-2026)

Table 29. North America Molecular Affinity Detection Service Market Size by Type (2021-2026) & (US$ Million)

Table 30. North America Molecular Affinity Detection Service Market Size by Application (2021-2026) & (US$ Million)

Table 31. Europe Molecular Affinity Detection Service Revenue by Company (2021-2026) & (US$ Million)

Table 32. Europe Molecular Affinity Detection Service Market Share by Revenue, by Company (2021-2026)

Table 33. Europe Molecular Affinity Detection Service Market Size by Type (2021-2026) & (US$ Million)

Table 34. Europe Molecular Affinity Detection Service Market Size by Application (2021-2026) & (US$ Million)

Table 35. China Molecular Affinity Detection Service Revenue by Company (2021-2026) & (US$ Million)

Table 36. China Molecular Affinity Detection Service Market Share by Revenue, by Company (2021-2026)

Table 37. China Molecular Affinity Detection Service Market Size by Type (2021-2026) & (US$ Million)

Table 38. China Molecular Affinity Detection Service Market Size by Application (2021-2026) & (US$ Million)

Table 39. Japan Molecular Affinity Detection Service Revenue by Company (2021-2026) & (US$ Million)

Table 40. Japan Molecular Affinity Detection Service Market Share by Revenue, by Company (2021-2026)

Table 41. Japan Molecular Affinity Detection Service Market Size by Type (2021-2026) & (US$ Million)

Table 42. Japan Molecular Affinity Detection Service Market Size by Application (2021-2026) & (US$ Million)

Table 43. Charles River Laboratories Company Details

Table 44. Charles River Laboratories Business Overview

Table 45. Charles River Laboratories Molecular Affinity Detection Service Product

Table 46. Charles River Laboratories Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 47. Charles River Laboratories Recent Development

Table 48. WuXi Biologics Company Details

Table 49. WuXi Biologics Business Overview

Table 50. WuXi Biologics Molecular Affinity Detection Service Product

Table 51. WuXi Biologics Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 52. WuXi Biologics Recent Development

Table 53. Pharmaron Company Details

Table 54. Pharmaron Business Overview

Table 55. Pharmaron Molecular Affinity Detection Service Product

Table 56. Pharmaron Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 57. Pharmaron Recent Development

Table 58. Evotec Company Details

Table 59. Evotec Business Overview

Table 60. Evotec Molecular Affinity Detection Service Product

Table 61. Evotec Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 62. Evotec Recent Development

Table 63. Sygnature Discovery Company Details

Table 64. Sygnature Discovery Business Overview

Table 65. Sygnature Discovery Molecular Affinity Detection Service Product

Table 66. Sygnature Discovery Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 67. Sygnature Discovery Recent Development

Table 68. Reaction Biology Company Details

Table 69. Reaction Biology Business Overview

Table 70. Reaction Biology Molecular Affinity Detection Service Product

Table 71. Reaction Biology Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 72. Reaction Biology Recent Development

Table 73. Domainex Company Details

Table 74. Domainex Business Overview

Table 75. Domainex Molecular Affinity Detection Service Product

Table 76. Domainex Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 77. Domainex Recent Development

Table 78. Selvita Company Details

Table 79. Selvita Business Overview

Table 80. Selvita Molecular Affinity Detection Service Product

Table 81. Selvita Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 82. Selvita Recent Development

Table 83. NovAliX Company Details

Table 84. NovAliX Business Overview

Table 85. NovAliX Molecular Affinity Detection Service Product

Table 86. NovAliX Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 87. NovAliX Recent Development

Table 88. 2bind Company Details

Table 89. 2bind Business Overview

Table 90. 2bind Molecular Affinity Detection Service Product

Table 91. 2bind Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 92. 2bind Recent Development

Table 93. RoukenBio Company Details

Table 94. RoukenBio Business Overview

Table 95. RoukenBio Molecular Affinity Detection Service Product

Table 96. RoukenBio Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 97. RoukenBio Recent Development

Table 98. ProteoGenix Company Details

Table 99. ProteoGenix Business Overview

Table 100. ProteoGenix Molecular Affinity Detection Service Product

Table 101. ProteoGenix Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 102. ProteoGenix Recent Development

Table 103. Creative Biolabs Company Details

Table 104. Creative Biolabs Business Overview

Table 105. Creative Biolabs Molecular Affinity Detection Service Product

Table 106. Creative Biolabs Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 107. Creative Biolabs Recent Development

Table 108. Ichor Life Sciences Company Details

Table 109. Ichor Life Sciences Business Overview

Table 110. Ichor Life Sciences Molecular Affinity Detection Service Product

Table 111. Ichor Life Sciences Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 112. Ichor Life Sciences Recent Development

Table 113. GenScript Biotech Company Details

Table 114. GenScript Biotech Business Overview

Table 115. GenScript Biotech Molecular Affinity Detection Service Product

Table 116. GenScript Biotech Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 117. GenScript Biotech Recent Development

Table 118. Sino Biological Company Details

Table 119. Sino Biological Business Overview

Table 120. Sino Biological Molecular Affinity Detection Service Product

Table 121. Sino Biological Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 122. Sino Biological Recent Development

Table 123. Viva Biotech Company Details

Table 124. Viva Biotech Business Overview

Table 125. Viva Biotech Molecular Affinity Detection Service Product

Table 126. Viva Biotech Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 127. Viva Biotech Recent Development

Table 128. KMD Bioscience Company Details

Table 129. KMD Bioscience Business Overview

Table 130. KMD Bioscience Molecular Affinity Detection Service Product

Table 131. KMD Bioscience Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 132. KMD Bioscience Recent Development

Table 133. Toray Research Center Company Details

Table 134. Toray Research Center Business Overview

Table 135. Toray Research Center Molecular Affinity Detection Service Product

Table 136. Toray Research Center Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 137. Toray Research Center Recent Development

Table 138. Fukushima Cell Factory Company Details

Table 139. Fukushima Cell Factory Business Overview

Table 140. Fukushima Cell Factory Molecular Affinity Detection Service Product

Table 141. Fukushima Cell Factory Revenue in Molecular Affinity Detection Service Business (2021-2026) & (US$ Million)

Table 142. Fukushima Cell Factory Recent Development

Table 143. Molecular Affinity Detection Service Market Trends

Table 144. Molecular Affinity Detection Service Market Drivers

Table 145. Molecular Affinity Detection Service Market Challenges

Table 146. Molecular Affinity Detection Service Market Restraints

Table 147. Research Programs/Design for This Report

Table 148. Key Data Information from Secondary Sources

Table 149. Key Data Information from Primary Sources

List of Figures

Figure 1. Molecular Affinity Detection Service Product Picture

Figure 2. Global Molecular Affinity Detection Service Market Share by Type: 2025 vs 2032

Figure 3. Binary Interaction Service (2 Molecular Components) Features

Figure 4. Ternary Interaction Service (3 Molecular Components) Features

Figure 5. Multi-Component Interaction Service (≥4 Molecular Components) Features

Figure 6. Global Molecular Affinity Detection Service Market Share by Application: 2025 vs 2032

Figure 7. Biopharmaceutical Industry

Figure 8. Research Institutes and Universities

Figure 9. Food Industry

Figure 10. Others

Figure 11. Molecular Affinity Detection Service Report Years Considered

Figure 12. Global Molecular Affinity Detection Service Market Size (US$ Million), Year-over-Year: 2021-2032

Figure 13. Global Molecular Affinity Detection Service Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global Molecular Affinity Detection Service Market Share by Revenue, by Region: 2021 vs 2025

Figure 15. North America Molecular Affinity Detection Service Revenue (US$ Million) Growth Rate (2021-2032)

Figure 16. Europe Molecular Affinity Detection Service Revenue (US$ Million) Growth Rate (2021-2032)

Figure 17. China Molecular Affinity Detection Service Revenue (US$ Million) Growth Rate (2021-2032)

Figure 18. Japan Molecular Affinity Detection Service Revenue (US$ Million) Growth Rate (2021-2032)

Figure 19. Global Molecular Affinity Detection Service Market Share by Players in 2025

Figure 20. Global Top Molecular Affinity Detection Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Molecular Affinity Detection Service as of 2025)

Figure 21. The Top 10 and 5 Players Market Share by Molecular Affinity Detection Service Revenue in 2025

Figure 22. North America Molecular Affinity Detection Service Market Share by Type (2021-2026)

Figure 23. North America Molecular Affinity Detection Service Market Share by Application (2021-2026)

Figure 24. Europe Molecular Affinity Detection Service Market Share by Type (2021-2026)

Figure 25. Europe Molecular Affinity Detection Service Market Share by Application (2021-2026)

Figure 26. China Molecular Affinity Detection Service Market Share by Type (2021-2026)

Figure 27. China Molecular Affinity Detection Service Market Share by Application (2021-2026)

Figure 28. Japan Molecular Affinity Detection Service Market Share by Type (2021-2026)

Figure 29. Japan Molecular Affinity Detection Service Market Share by Application (2021-2026)

Figure 30. Charles River Laboratories Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 31. WuXi Biologics Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 32. Pharmaron Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 33. Evotec Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 34. Sygnature Discovery Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 35. Reaction Biology Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 36. Domainex Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 37. Selvita Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 38. NovAliX Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 39. 2bind Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 40. RoukenBio Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 41. ProteoGenix Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 42. Creative Biolabs Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 43. Ichor Life Sciences Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 44. GenScript Biotech Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 45. Sino Biological Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 46. Viva Biotech Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 47. KMD Bioscience Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 48. Toray Research Center Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 49. Fukushima Cell Factory Revenue Growth Rate in Molecular Affinity Detection Service Business (2021-2026)

Figure 50. Bottom-up and Top-down Approaches for This Report

Figure 51. Data Triangulation

Figure 52. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Molecular Affinity Detection Service in 2026? zhanKai

The global market size of Molecular Affinity Detection Service in 2026 was 692 Million USD.

Which region is expected to have the highest market share? shouQi

What is the annual compound growth rate of the global Molecular Affinity Detection Service market size from 2026 to 2032? shouQi

What was the global market size of Molecular Affinity Detection Service in 2032? shouQi

Which companies rank high in the global Molecular Affinity Detection Service market? shouQi

Related Reports

Global Molecular Affinity Detection Service Market Research Report 2026
The global Molecular Affinity Detection Service market was valued at US$ 621 million in 2025 and is anticipated to reach US$ 1330 million by 2032, at a CAGR of 11.5% from 2026 to 2032.
Published Date: 2026-08-06
Pages: 140
USD 2900.00
(Single User License)
Global Molecular Affinity Detection Service Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Molecular Affinity Detection Service market is projected to grow from US$ 621 million in 2025 to US$ 1330 million by 2032, at a CAGR of 11.5% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-08-06
Pages: 147
USD 4900.00
(Single User License)
Molecular Affinity Detection Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Molecular Affinity Detection Service was estimated to be worth US$ 621 million in 2025 and is projected to reach US$ 1330 million, growing at a CAGR of 11.5% from 2026 to 2032.
Published Date: 2026-08-06
Pages: 132
USD 3950.00
(Single User License)

Global Molecular Affinity Detection Service Market Research Report 2026
The global Molecular Affinity Detection Service market was valued at US$ 621 million in 2025 and is anticipated to reach US$ 1330 million by 2032, at a CAGR of 11.5% from 2026 to 2032.
Published: 2026-08-06
Pages: 140
USD 2900.00 (Single User License)
Global Molecular Affinity Detection Service Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Molecular Affinity Detection Service market is projected to grow from US$ 621 million in 2025 to US$ 1330 million by 2032, at a CAGR of 11.5% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-08-06
Pages: 147
USD 4900.00 (Single User License)
Molecular Affinity Detection Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Molecular Affinity Detection Service was estimated to be worth US$ 621 million in 2025 and is projected to reach US$ 1330 million, growing at a CAGR of 11.5% from 2026 to 2032.
Published: 2026-08-06
Pages: 132
USD 3950.00 (Single User License)